Public Health Pharmacogenomics and the Design Principles for Global Public Goods - Moving Genomics to Responsible Innovation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. A Mobilising Concept? Unpacking Academic Representations of Responsible Research and Innovation.Science and engineering ethics · 2017
   Article
2. Bernard Lerer: recipient of the 2014 inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics).Omics : a journal of integrative biology · 2014
   Article
3. Ethical, Political and Societal Implications of the Open Access Journal Movement in the Era of Economic Crisis, with Emphasis on Public Health Pharmacogenomics.Current pharmacogenomics and personalized medicine · 2013
   Article
4. All the post-genomic world is a stage: the actors and narrators required for translating pharmacogenomics into public health.Personalized medicine · 2013
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

10 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as